Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) rose 1.7% on Wednesday . The company traded as high as $10.60 and last traded at $10.49, approximately 377,846 shares traded hands during mid-day trading. A decline of 70% from the average daily volume of 1,265,486 shares. The stock had previously closed at $10.31.

Several research firms have weighed in on KPTI. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective (up previously from $29.00) on shares of Karyopharm Therapeutics in a research note on Friday, July 5th. BidaskClub cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. Wedbush raised their target price on shares of Karyopharm Therapeutics from $6.00 to $11.00 in a research note on Monday, July 8th. ValuEngine upgraded shares of Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 5th. Finally, Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, July 13th. One analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $17.32.

The company has a quick ratio of 6.93, a current ratio of 6.93 and a debt-to-equity ratio of 1.46. The firm has a market cap of $600.01 million, a P/E ratio of -3.32 and a beta of 2.41. The business has a fifty day moving average of $8.85 and a 200 day moving average of $6.43.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.26. The firm had revenue of $9.49 million for the quarter. Karyopharm Therapeutics had a negative return on equity of 154.75% and a negative net margin of 2,138.80%. Research analysts expect that Karyopharm Therapeutics Inc will post -3.64 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Orbimed Advisors LLC acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $18,859,000. Nuveen Asset Management LLC acquired a new stake in Karyopharm Therapeutics during the 2nd quarter valued at $2,310,000. UBS Asset Management Americas Inc. lifted its holdings in Karyopharm Therapeutics by 101.2% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 26,976 shares of the company’s stock valued at $162,000 after purchasing an additional 13,571 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its position in Karyopharm Therapeutics by 80.4% during the second quarter. D. E. Shaw & Co. Inc. now owns 805,462 shares of the company’s stock worth $4,824,000 after purchasing an additional 359,087 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its position in Karyopharm Therapeutics by 372.1% during the second quarter. Cubist Systematic Strategies LLC now owns 84,504 shares of the company’s stock worth $506,000 after purchasing an additional 66,603 shares during the period. Institutional investors own 82.58% of the company’s stock.

Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Featured Article: Why are percentage decliners important?

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.